Evidence map›Paper›PMID 42356529›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Immunosuppressive Pathways in Cutaneous Melanoma: Functional Integration Between PD-1 and CD73 and Therapeutic Implications.

Rayana Vilela Bertolucci, Bruna Klein, Camilla Casarin Pase, Vitória Capelli de Melo, Margarete Dulce Bagatini

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rayana Vilela BertolucciMedical School, Federal University of Fronteira Sul, Campus Chapecó, Chapecó 89815-899, Santa Catarina, Brazil.ORCID 0009-0008-1393-1791
Bruna KleinPostgraduate Program in Biomedical Sciences, Federal University of Fronteira Sul, Campus Chapecó, Chapecó 89815-899, Santa Catarina, Brazil.ORCID 0000-0002-9986-3118
Camilla Casarin PaseMedical School, Federal University of Fronteira Sul, Campus Chapecó, Chapecó 89815-899, Santa Catarina, Brazil.ORCID 0009-0003-5637-6154
Vitória Capelli de MeloMedical School, Federal University of Fronteira Sul, Campus Chapecó, Chapecó 89815-899, Santa Catarina, Brazil.ORCID 0000-0002-4286-5083
Margarete Dulce BagatiniPostgraduate Program in Biomedical Sciences, Federal University of Fronteira Sul, Campus Chapecó, Chapecó 89815-899, Santa Catarina, Brazil.

Funding

Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina 2023TR001472Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina 2024TR002502Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina 2025TR001686Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina 2026TR000240National Council for Scientific and Technological Development 305974/2025-4National Council for Scientific and Technological Development Instituto Nacional Sinalização Purinérgica: Desafios para a saúde do século 21; Nº 409156/2024-8
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune checkpoint inhibitorsimmunosuppressionmelanomapurinergic signalingresistance to immunotherapytumor microenvironment

Identifiers

PMID42356529
PMCPMC13305712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.